Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9566441 | 1.00 | SIGMAR1 (0.56) | SIGMAR1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL9566495 | 0.93 | KDM4E (0.53) | SIGMAR1CYP3A4CYP2D6ALDH1A1KDM4E | |
| SCHEMBL30803151 | 0.88 | CYP2D6 (0.50) | SIGMAR1CYP3A4CYP2D6ALDH1A1MEN1 | |
| SCHEMBL20455789 | 0.86 | ALDH1A1 (0.51) | SIGMAR1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4509900 | 0.83 | ALDH1A1 (0.50) | SIGMAR1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL30751751 | 0.81 | L3MBTL1 (0.49) | SIGMAR1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL22864682 | 0.81 | L3MBTL1 (0.49) | SIGMAR1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL30751712 | 0.81 | SIGMAR1 (0.48) | SIGMAR1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL9566374 | 0.81 | MEN1 (0.48) | SIGMAR1CYP2C9CYP2C19ALDH1A1GAA | |
| SCHEMBL16053764 | 0.80 | L3MBTL1 (0.48) | SIGMAR1CYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0550025-A1 | Azaspiroheptanes and octanes and processes for their production | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1993-07-07 | — | — | EP | claimed |
| US-7582627-B2 | 3-Amino-7-[3-(1-aminoethyl)-4-fluoropyrrolidin-1-yl]-1-cyclopropyl-8-methyl-1H-pyrido[4,3-d]pyrimidine-2,4-dione; quinolone antibiotics; bactericides; for antibiotic- resistant bacterial infections, ciprofloxacin- resistant ones; inhibiting wild-type and quinolone- resistant mutants of DNA gryase | WARNER-LAMBERT COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1255739-B1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | WARNER LAMBERT CO (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20060287308-A1 | 3-Aminoquinazolin-2,4-dione antibacterial agents | ZOETIS WLC LLC | 2006-12-21 | — | — | US | disclosed |
| US-7094780-B1 | 3-aminoquinazolin-2,4-dione antibacterial agents | WARNER LAMBERT COMPANY LLC (US) | 2006-08-22 | — | — | US | disclosed |
| US-20060183762-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | ZOETIS WLC LLC | 2006-08-17 | — | — | US | disclosed |
| EP-1255739-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001053273-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2001-07-26 | — | — | WO | disclosed |
| EP-0550025-A1 | Azaspiroheptanes and octanes and processes for their production | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1993-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183762-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | ABL1, NQO2, CBR3 | SIGMAR1 274/4885CYP3A4 1188/4885CYP2D6 730/4885 |
| US-20060287308-A1 | 3-Aminoquinazolin-2,4-dione antibacterial agents | ABL1, NQO2, AAAS | SIGMAR1 272/4885CYP3A4 1134/4885CYP2D6 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.